drugset / Trial / NCT00343733

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

NCT00343733

Phase 3 Completed 120 enrolled Cephalon
RandomizedDouble-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of OraVescent fentanyl treatment compared to placebo treatment monthly over a 12-week treatment period in alleviating breakthrough pain (BTP) in opioid-tolerant patients with noncancer-related chronic pain.

Timeline

Start
2006-08
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified

Indications

No indication recorded.